A new multidimensional framework proposes bypassing HLA-Ia downregulation in glioblastoma by leveraging HLA-E presentation, gamma-delta T cells, and AI-driven prioritization to create genotype-agnostic neoantigen therapies.
This approach aims to overcome key barriers like intratumoral heterogeneity and the blood-brain barrier, potentially enabling broader off-the-shelf applications.
Nothing published in the last 14 days cleared the bar. Below is the most relevant background we're tracking.
Relevant work from earlier we're still surfacing — not today's news.